Do analysts recommend PRTA or MESO?

Prothena currently has a consensus target price of $23.75, indicating a potential upside of 137.03%. Given Prothena's stronger consensus rating and higher probable upside, research analysts clearly believe Prothena is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has stronger earnings and valuation, PRTA or MESO?

Mesoblast has higher revenue and earnings than Prothena. Mesoblast is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 54.19 -$244.09M -$2.82 N/A Mesoblast $17.20M 99.28 -$102.14M -$0.54 N/A

Is PRTA or MESO more profitable?

Mesoblast has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Mesoblast's return on equity of 0.00% beat Prothena's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -260.92% -43.44% -36.87% Mesoblast N/A N/A N/A

Does the media refer more to PRTA or MESO?

In the previous week, Mesoblast had 1 more articles in the media than Prothena. MarketBeat recorded 3 mentions for Mesoblast and 2 mentions for Prothena. Prothena's average media sentiment score of 0.88 beat Mesoblast's score of 0.81 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ADMA or PRTA?

ADMA Biologics has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $510.17M 3.97 $146.93M $0.68 12.86 Prothena $9.68M 54.19 -$244.09M -$2.82 N/A

Is ADMA or PRTA more profitable?

ADMA Biologics has a net margin of 32.43% compared to Prothena's net margin of -260.92%. ADMA Biologics' return on equity of 39.98% beat Prothena's return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.43% 39.98% 28.08% Prothena -260.92% -43.44% -36.87%

Does the media prefer ADMA or PRTA?

In the previous week, ADMA Biologics had 37 more articles in the media than Prothena. MarketBeat recorded 39 mentions for ADMA Biologics and 2 mentions for Prothena. Prothena's average media sentiment score of 0.88 beat ADMA Biologics' score of 0.04 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 4 Positive mention(s) 32 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Prothena 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TSHA or PRTA?

In the previous week, Taysha Gene Therapies had 13 more articles in the media than Prothena. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 2 mentions for Prothena. Prothena's average media sentiment score of 0.88 beat Taysha Gene Therapies' score of 0.44 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, HRMY or PRTA?

Harmony Biosciences has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harmony Biosciences $868.45M 2.36 $158.69M $2.48 14.30 Prothena $9.68M 54.19 -$244.09M -$2.82 N/A

Does the media favor NRIX or PRTA?

In the previous week, Nurix Therapeutics had 5 more articles in the media than Prothena. MarketBeat recorded 7 mentions for Nurix Therapeutics and 2 mentions for Prothena. Prothena's average media sentiment score of 0.88 beat Nurix Therapeutics' score of 0.56 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prothena (PRTA) Competitors

$10.02 +0.75 (+8.09%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$9.82 -0.21 (-2.05%)

As of 06/26/2026 07:34 PM Eastern

Compare

PRTA vs. MESO, ADMA, TSHA, HRMY, and NRIX

Should you buy Prothena stock or one of its competitors? MarketBeat compares Prothena with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prothena include Mesoblast (MESO), ADMA Biologics (ADMA), Taysha Gene Therapies (TSHA), Harmony Biosciences (HRMY), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.

How does Prothena compare to Mesoblast?

Prothena (NASDAQ:PRTA) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

97.1% of Prothena shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 10.4% of Prothena shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Prothena currently has a consensus target price of $23.75, indicating a potential upside of 137.03%. Given Prothena's stronger consensus rating and higher probable upside, research analysts clearly believe Prothena is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Prothena has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

Mesoblast has higher revenue and earnings than Prothena. Mesoblast is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	54.19	-$244.09M	-$2.82	N/A
Mesoblast	$17.20M	99.28	-$102.14M	-$0.54	N/A

In the previous week, Mesoblast had 1 more articles in the media than Prothena. MarketBeat recorded 3 mentions for Mesoblast and 2 mentions for Prothena. Prothena's average media sentiment score of 0.88 beat Mesoblast's score of 0.81 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesoblast has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Mesoblast's return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Mesoblast	N/A	N/A	N/A

Summary

Mesoblast beats Prothena on 10 of the 16 factors compared between the two stocks.

How does Prothena compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

ADMA Biologics presently has a consensus price target of $19.67, suggesting a potential upside of 124.89%. Prothena has a consensus price target of $23.75, suggesting a potential upside of 137.03%. Given Prothena's stronger consensus rating and higher probable upside, analysts plainly believe Prothena is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

ADMA Biologics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Prothena has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

In the previous week, ADMA Biologics had 37 more articles in the media than Prothena. MarketBeat recorded 39 mentions for ADMA Biologics and 2 mentions for Prothena. Prothena's average media sentiment score of 0.88 beat ADMA Biologics' score of 0.04 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	4 Positive mention(s)	32 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Prothena	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.97	$146.93M	$0.68	12.86
Prothena	$9.68M	54.19	-$244.09M	-$2.82	N/A

ADMA Biologics has a net margin of 32.43% compared to Prothena's net margin of -260.92%. ADMA Biologics' return on equity of 39.98% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Prothena	-260.92%	-43.44%	-36.87%

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ADMA Biologics beats Prothena on 9 of the 17 factors compared between the two stocks.

How does Prothena compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Prothena has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

In the previous week, Taysha Gene Therapies had 13 more articles in the media than Prothena. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 2 mentions for Prothena. Prothena's average media sentiment score of 0.88 beat Taysha Gene Therapies' score of 0.44 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Prothena	-260.92%	-43.44%	-36.87%

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Taysha Gene Therapies presently has a consensus price target of $12.38, indicating a potential upside of 95.34%. Prothena has a consensus price target of $23.75, indicating a potential upside of 137.03%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Taysha Gene Therapies has higher revenue and earnings than Prothena. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	186.48	-$109M	-$0.38	N/A
Prothena	$9.68M	54.19	-$244.09M	-$2.82	N/A

Summary

Taysha Gene Therapies beats Prothena on 10 of the 17 factors compared between the two stocks.

How does Prothena compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Prothena had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 2 mentions for Prothena and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.91 beat Prothena's score of 0.88 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Harmony Biosciences	Very Positive
Prothena	Positive

Harmony Biosciences has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.36	$158.69M	$2.48	14.30
Prothena	$9.68M	54.19	-$244.09M	-$2.82	N/A

Harmony Biosciences presently has a consensus target price of $40.89, suggesting a potential upside of 15.28%. Prothena has a consensus target price of $23.75, suggesting a potential upside of 137.03%. Given Prothena's stronger consensus rating and higher probable upside, analysts clearly believe Prothena is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Harmony Biosciences has a net margin of 16.20% compared to Prothena's net margin of -260.92%. Harmony Biosciences' return on equity of 17.19% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Prothena	-260.92%	-43.44%	-36.87%

Harmony Biosciences has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Prothena has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Summary

Harmony Biosciences beats Prothena on 10 of the 16 factors compared between the two stocks.

How does Prothena compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Prothena has a net margin of -260.92% compared to Nurix Therapeutics' net margin of -411.37%. Prothena's return on equity of -43.44% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Prothena	-260.92%	-43.44%	-36.87%

97.1% of Prothena shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Prothena has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	28.20	-$264.46M	-$3.16	N/A
Prothena	$9.68M	54.19	-$244.09M	-$2.82	N/A

Nurix Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Prothena has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Nurix Therapeutics presently has a consensus price target of $32.20, suggesting a potential upside of 40.61%. Prothena has a consensus price target of $23.75, suggesting a potential upside of 137.03%. Given Prothena's higher possible upside, analysts clearly believe Prothena is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Nurix Therapeutics had 5 more articles in the media than Prothena. MarketBeat recorded 7 mentions for Nurix Therapeutics and 2 mentions for Prothena. Prothena's average media sentiment score of 0.88 beat Nurix Therapeutics' score of 0.56 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prothena beats Nurix Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Prothena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTA vs. The Competition

Export

Metric	Prothena	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$524.58M	$3.63B	$7.04B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.24%
P/E Ratio	-3.55	21.56	26.13	24.17
Price / Sales	54.19	334.27	600.51	118.90
Price / Cash	N/A	141.14	47.95	55.62
Price / Book	1.92	8.33	10.78	6.36
Net Income	-$244.09M	$23.91M	$3.58B	$337.99M
7 Day Performance	12.21%	3.42%	2.22%	0.10%
1 Month Performance	0.40%	0.39%	-0.09%	-1.28%
1 Year Performance	64.80%	65.22%	34.39%	27.68%

Prothena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTA Prothena	2.7832 of 5 stars	$10.02 +8.1%	$23.75 +137.0%	+64.8%	$524.58M	$9.68M	N/A	130	Analyst Upgrade High Trading Volume
MESO Mesoblast	1.2647 of 5 stars	$15.37 -0.8%	N/A	+20.8%	$1.99B	$65.38M	N/A	80	Gap Down
ADMA ADMA Biologics	4.3901 of 5 stars	$8.58 +0.1%	$19.67 +129.3%	-51.8%	$1.99B	$509.86M	12.61	530	Trending News
TSHA Taysha Gene Therapies	3.0667 of 5 stars	$6.81 +4.2%	$11.91 +75.0%	+166.4%	$1.95B	$9.77M	N/A	180	News Coverage Analyst Forecast
HRMY Harmony Biosciences	4.5056 of 5 stars	$33.61 +0.5%	$40.89 +21.7%	+10.9%	$1.95B	$868.45M	13.55	200	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTA) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prothena (PRTA) Competitors

PRTA vs. MESO, ADMA, TSHA, HRMY, and NRIX

How does Prothena compare to Mesoblast?

Summary

How does Prothena compare to ADMA Biologics?

Summary

How does Prothena compare to Taysha Gene Therapies?

Summary

How does Prothena compare to Harmony Biosciences?

Summary

How does Prothena compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prothena (PRTA) Competitors

PRTA vs. MESO, ADMA, TSHA, HRMY, and NRIX

How does Prothena compare to Mesoblast?

Do insiders and institutionals believe in PRTA or MESO?

Do analysts recommend PRTA or MESO?

Which has more risk & volatility, PRTA or MESO?

Which has stronger earnings and valuation, PRTA or MESO?

Does the media refer more to PRTA or MESO?

Is PRTA or MESO more profitable?

Summary

How does Prothena compare to ADMA Biologics?

Do analysts rate ADMA or PRTA?

Which has more volatility and risk, ADMA or PRTA?

Does the media prefer ADMA or PRTA?

Which has preferable earnings & valuation, ADMA or PRTA?

Is ADMA or PRTA more profitable?

Do insiders & institutionals hold more shares of ADMA or PRTA?

Summary

How does Prothena compare to Taysha Gene Therapies?

Which has more risk & volatility, TSHA or PRTA?

Does the media prefer TSHA or PRTA?

Is TSHA or PRTA more profitable?

Do institutionals & insiders believe in TSHA or PRTA?

Do analysts prefer TSHA or PRTA?

Which has stronger valuation & earnings, TSHA or PRTA?

Summary

How does Prothena compare to Harmony Biosciences?

Do institutionals and insiders hold more shares of HRMY or PRTA?

Does the media favor HRMY or PRTA?

Which has higher valuation and earnings, HRMY or PRTA?

Do analysts recommend HRMY or PRTA?

Is HRMY or PRTA more profitable?

Which has more risk & volatility, HRMY or PRTA?

Summary

How does Prothena compare to Nurix Therapeutics?

Is NRIX or PRTA more profitable?

Do institutionals & insiders hold more shares of NRIX or PRTA?

Which has preferable earnings and valuation, NRIX or PRTA?

Which has more volatility and risk, NRIX or PRTA?

Do analysts prefer NRIX or PRTA?

Does the media favor NRIX or PRTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools